Yao Bin, Li Min, Pang Ying
Department of Pediatrics, East Ward, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu 610110, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2013 Nov;15(11):1018-22.
To evaluate the effect of early intervention with Mycobacterium phlei F.U.36 injection on the balance of CD4⁺CD25⁺ regulatory T cells and Th17 cells in asthmatic mice, and to investigate the immunomodulatory effect of Mycobacterium phlei F.U.36.
Thirty female BALB/c mice were randomly divided into three groups: normal control (n=10), asthma model (n=10) and Mycobacterium phlei F.U.36 treatment groups (n=10). A mouse model of asthma was prepared by injection and aerosol inhalation of chicken ovalbumin in the asthma model and Mycobacterium phlei F.U.36 treatment groups, while mice in the normal control group were given normal saline instead. The treatment group was intraperitoneally injected with Mycobacterium phlei F.U.36 (0.57 μg, once every other day) three times in the first two weeks after the first sensitization. All mice were sacrificed at 24 hours after the last challenge. Left lung tissues of these mice were obtained and made into sections for observation of inflammatory changes. The percentages of CD4⁺CD25⁺ regulatory T cells and Th17 cells in CD4⁺ T cells among splenic mononuclear cells were determined by flow cytometry. The levels of interleukin (IL)-10 and IL-17 in serum and bronchoalveolar lavage fluid were measured using ELISA.
Compared with the normal control group, the asthma model group had significantly decreased percentages of CD4⁺CD25⁺ regulatory T cells and IL-10 levels (P<0.05) and significantly increased percentages of Th17 cells and IL-17 levels (P<0.05). Compared with the asthma model group, the Mycobacterium phlei F.U.36 treatment group had significantly increased percentages of CD4⁺CD25⁺ regulatory T cells and IL-10 levels (P<0.05) and significantly decreased percentage of Th17 cells and IL-17 levels (P<0.05).
Early intervention with Mycobacterium phlei F.U.36 can promote development of CD4⁺CD25⁺ regulatory T cells and production of IL-10 and inhibit generation of Th17 cells and production of IL-17 in asthmatic mice.
评估草分枝杆菌F.U.36注射早期干预对哮喘小鼠CD4⁺CD25⁺调节性T细胞和Th17细胞平衡的影响，并探讨草分枝杆菌F.U.36的免疫调节作用。
将30只雌性BALB/c小鼠随机分为三组：正常对照组（n = 10）、哮喘模型组（n = 10）和草分枝杆菌F.U.36治疗组（n = 10）。哮喘模型组和草分枝杆菌F.U.36治疗组通过注射和雾化吸入鸡卵白蛋白制备哮喘小鼠模型，正常对照组小鼠给予生理盐水。治疗组在首次致敏后的前两周内每隔一天腹腔注射草分枝杆菌F.U.36（0.57μg），共三次。末次激发后24小时处死所有小鼠。获取这些小鼠的左肺组织并制成切片观察炎症变化。采用流式细胞术测定脾单个核细胞中CD4⁺T细胞内CD4⁺CD25⁺调节性T细胞和Th17细胞的百分比。采用酶联免疫吸附测定法检测血清和支气管肺泡灌洗液中白细胞介素（IL）-10和IL-17的水平。
与正常对照组相比，哮喘模型组CD4⁺CD25⁺调节性T细胞百分比和IL-10水平显著降低（P < 0.05），Th17细胞百分比和IL-17水平显著升高（P < 0.05）。与哮喘模型组相比，草分枝杆菌F.U.36治疗组CD4⁺CD25⁺调节性T细胞百分比和IL-10水平显著升高（P < 0.05），Th17细胞百分比和IL-17水平显著降低（P < 0.05）。
草分枝杆菌F.U.36早期干预可促进哮喘小鼠CD4⁺CD25⁺调节性T细胞的发育及IL-10的产生，抑制Th17细胞的生成及IL-17的产生。
